Endokrine Therapie des fortgeschrittenen Prostatakarzinoms

  • G. Bartsch
  • P. J. Oefner
  • J. Eberle


Obwohl der Einfluß des Hodens auf Wachstum und Funktion der Prostata bereits im 19. Jahrhundert vermutet worden war, konnte dies erst durch die Pionierarbeiten von Huggins u. Stevens bestätigt werden. Es entstand das Konzept der Androgenabhängigkeit des Prostatagewebes [14].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Asselin J, Labrie F, Gourdeau J, Bonne C, Raynaud JP (1976) Binding of 3H- methyltrienolone (R-1881) in rat prostate and human benign prostatic hypertrophy ( BPH ). Steroids 28: 449–459PubMedCrossRefGoogle Scholar
  2. 2.
    Barrack ER, Coffey DS (1980) The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem 255: 7265–7275PubMedGoogle Scholar
  3. 3.
    Bartsch G, Müller HR, Oberholzer M, Rohr HP (1979) Light microscopic stereological analysis of the normal human prostate and of benign prostate hyperplasia. J Urol 122: 487–491PubMedGoogle Scholar
  4. 4.
    Bonne C, Raynaud JP (1975) Methyltrienolone, a specific ligand for cellular androgen receptors. Steroids 26: 227–232PubMedCrossRefGoogle Scholar
  5. 5.
    Bruchovsky N, Lesser B, Van Doom E, Craven S (1975) Hormonal effects on cell proliferation in rat prostate. Vitam Horm 33: 61–102PubMedCrossRefGoogle Scholar
  6. 6.
    Bruchovsky N, Callaway T, Lieskovsky G, Rennie PS (1980) Markers of androgen action in human prostate: potential use in the clinical assessment of prostatic carcinoma. In: Witliff JL, Dapunt O (eds) Steroid receptors and hormone dependent neoplasia. Masson Publ USA, New York, pp 121–132Google Scholar
  7. 7.
    Caine M, Perlberg S, Gordon R (1975) The treatment of benign prostatic hypertrophy with flutamide (SCH-13521): A placebo controlled study. J Urol 114: 564–568PubMedGoogle Scholar
  8. 8.
    Corbin A (1982) From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J Biol Med 55: 27–47PubMedGoogle Scholar
  9. 9.
    Cowan RA, Cowan SK, Grant JK, Elder H Y (1977) Biochemical investigations of separated epithelium and stroma from benign prostatic hyperplastic tissue. J Endocrinol 74: 111–116PubMedCrossRefGoogle Scholar
  10. 10.
    De Krester DM, Catt KJ, Paulsen CA (1971) Studies on the in vitro testicular binding of iodinated luteinizing hormone in rats. Endocrinology 80: 332–337Google Scholar
  11. 11.
    Dhom G (1976) Pathology and classification of prostatic carcinoma. In: Marberger H, Haschek H, Schirmer HKA, Colston JAC, Witkin E (eds) Prostatic disease. Alan R Liss, New York, p 111Google Scholar
  12. 12.
    Dufau ML, Catt KJ (1973) Extraction of soluble gonadotropin receptors from rat testis. Nature 242: 246–248Google Scholar
  13. 13.
    Huggins C, Hodge CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297Google Scholar
  14. 14.
    Huggins C, Stevens RA (1940) The effect of castration on benign hypertrophy of the prostate in man. J Urol 43: 705–714Google Scholar
  15. 15.
    Huggins C, Stevens RA, Hodges CV (1941) Studies on prostatic cancer. II. The effects of ca¬stration on advanced carcinoma of the prostate gland. Arch Surg 43: 209–223Google Scholar
  16. 16.
    Isaacs JT (1982) Cellular factors in the development of resistance to hormonal therapy. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 139–156Google Scholar
  17. 17.
    Isaacs JT, Coffey DS (1979) Androgenic control of prostatic growth: regulation of steroid levels. UICC Monogr (Prostatic Cancer) 48: 112–122Google Scholar
  18. 18.
    Isaacs JT, Coffey DS (1981) Adaptation versus selection on the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070–5075PubMedGoogle Scholar
  19. 19.
    Isaacs JT, Coffey DS (1981) Androgen metabolism in the prostate: new concepts related to normal and abnormal growth. In: Altwein JE, Bartsch G, Jacobi GH (eds) Antihormone, Bedeutung in der Urologie. Zuckschwerdt, München, pp 3–20Google Scholar
  20. 20.
    Isaacs JT, Heston WDW, Weissmann RM, Coffey DS (1978) Animal models of the hormone- sensitive and insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 38: 4353–4359PubMedGoogle Scholar
  21. 21.
    Isaacs JT, Schulze H, Coffey DS (1987) Development of androgen resistance in prostatic cancer. In: Murphey GP, Khoury S, Kiiss R, Chatelain C, Denis L (eds) Prostate cancer, part A: Research, endocrine treatment, and histopathology. Liss, New York, pp 21–31Google Scholar
  22. 22.
    Jacobi GH, Altwein JE (1980) Androgenstoffwechsel im Prostatakarzinom: 3-Hydroxyste- roid-Dehydrogenase-Aktivität in Abhängigkeit vom Tumor-Differenzierungsgrad. Urol Intern 35: 194–205CrossRefGoogle Scholar
  23. 23.
    Jacobo E, Schmidt JD, Weinstein SH, Flocks RH (1976) Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 8: 231–233PubMedCrossRefGoogle Scholar
  24. 24.
    Krieg M, Klötzl G, Kaufmann J, Voigt KD (1981) Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding. Acta Endocrinol 96: 422–432PubMedGoogle Scholar
  25. 25.
    Ling V (1982) Genetic basis of drug resistance in mammalian cells. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 1–19Google Scholar
  26. 26.
    MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK (1979) Origin of estrogen in normal men and in women with testicular féminisation. J Clin Endocrinol Metab 49: 905–916PubMedCrossRefGoogle Scholar
  27. 27.
    Mackler MA, Liberti JP, Smith MJV, Koontz WW, Prout GR (1972) The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in parents with carcinoma of the prostate. Invest Urol 9: 423 – 425PubMedGoogle Scholar
  28. 28.
    Means AR, Vaitukaitis JL (1972) Peptide hormone receptors: specific binding of 3H-FSH to testis. Endocrinology 90: 39–46PubMedCrossRefGoogle Scholar
  29. 29.
    Menon M, Tananis CE, Hicks LL, Hawkins EF, McLoughlin HG, Walsh PC (1978) Characterisation of the binding of a potent synthetic androgen methyltrienolone, to human tissues. J Clin Invest 61: 150–162PubMedCrossRefGoogle Scholar
  30. 30.
    Morfin RF, Leav I, Chavles JF, Cavazos LF, Ofner P, Floch HH (1977) Correlative study of the morphology and C19-steroid metabolism of benign and cancerous human prostatic tissue. Cancer 39: 1517–1534PubMedCrossRefGoogle Scholar
  31. 31.
    Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma; clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320Google Scholar
  32. 32.
    Prout GR, Irwin RJ, Kliman B, Daly JJ, MacLaughlin RA, Griffin PP (1975) Prostatic cancer and SCH-13521. II. Histological alterations and the pituitary gonadal axis. J Urol 113: 834–840PubMedGoogle Scholar
  33. 33.
    Prout GR, Kliman B, Daly JJ, MacLaughlin RA, Griffin PD (1976) In vitro uptake of 3H- testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues. J Urol 116: 603–610PubMedGoogle Scholar
  34. 34.
    Rennie PS (1982) Biochemical aspects of androgen resistance. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 95–121Google Scholar
  35. 35.
    Robinson MRG, Thomas BS (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 4: 391–394PubMedCrossRefGoogle Scholar
  36. 36.
    Rohr HP, Bartsch G (1980) Human benign prostatic hyperplasia: a stromal disease. Urology 16: 625–633PubMedCrossRefGoogle Scholar
  37. 37.
    Romijn JC, Oishi K, Belt de Vries J, Schweikert U, Mulder E, Schröder FH (1980) Androgen metabolism and androgen receptors in separated epithelium and stroma of the human prostate. In: Schröder FH, de Voogt HJ (eds) Steroid receptors, metabolism and prostatic cancer. Excerpta Medica, Amsterdam, pp 134–139Google Scholar
  38. 38.
    Rosen V, Jung I, Baulieu EE, Roberl P (1975) Androgen binding proteins in human benign prostate hypertrophy. J Clin Endocrinol Metab 41: 761–770PubMedCrossRefGoogle Scholar
  39. 39.
    Schally AV, Arimura A, Kastin AJ (1973) The LH and FSH releasing hormone. In: Scow RO (ed) Endocrinology. Excerpta Medica, AmsterdamGoogle Scholar
  40. 40.
    Scheiber K, Mikuz G, Bartsch G (1984) Exocrine and endocrine functions in unilateral testicular disease. World J Urol 2: 251–254CrossRefGoogle Scholar
  41. 41.
    Schulze H, Isaacs JT, Coffey DS (1986) A critical review of the concept of total androgen abla¬tion in the treatment of prostate cancer. In: Murphy G (ed) 2nd International Symposium on Prostatic Cancer. Alan R Liss, New YorkGoogle Scholar
  42. 42.
    Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45: 1929–1936PubMedGoogle Scholar
  43. 43.
    Shain SA, Boesel RW (1978) Human prostate steroid hormone receptor quantitation: current methodology and possible utilization as a clinical discriminant in carcinoma. Invest Urol 16: 169–174PubMedGoogle Scholar
  44. 44.
    Shain SA, Boesel RW (1978) Androgen receptor content of the normal and hyperplastic canine prostate. J Clin Invest 61: 645–660CrossRefGoogle Scholar
  45. 45.
    Shain SA, Boesel RW, Lamm DL, Rodwin HM (1978) Characterization of unoccupied (R) and occupied ( RA) androgen binding components of the hyperplastic human prostate. Steroids 31: 541–556PubMedCrossRefGoogle Scholar
  46. 46.
    Shearer RJ, Hendry WF, Sommer IF, Ferguson JD (1973) Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668–677PubMedCrossRefGoogle Scholar
  47. 47.
    Siiteri PK, Wilson JD (1970) Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49: 1737–1745PubMedCrossRefGoogle Scholar
  48. 48.
    Sirett DAN, Grant JK (1978) Androgen binding in cytosols and nuclei of human benign hyperplastic tissue. J Endocrinol 77: 101–110PubMedCrossRefGoogle Scholar
  49. 49.
    Skipper HE, Schabel FM, Lloyd MM (1978) Selection and overgrowth of specifically and permanently drug-resistant tumor cells. Exp Ther Kinetics 15: 207–217Google Scholar
  50. 50.
    Smolev JK, Heston WDW, Scott WW, Coffey DS (1977) Characterization of the Dunning R-3327-H prostatic adenocarcinoma: An appropriate animal model for prostatic cancer. Cancer Treat Rep 61: 273–287PubMedGoogle Scholar
  51. 51.
    Trachtenberg J, Bujnovszky P, Walsh PC (1982) Androgen receptor content of normal and hyperplastic human prostate. J Clin Endocrinol Metab 54: 17–21PubMedCrossRefGoogle Scholar
  52. 52.
    Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017Google Scholar
  53. 53.
    Wagner RK (1972) Characterisation and assay of steroid hormone receptors and steroid binding serum proteins by agar gel electrophoresis at low temperature. Hoppe Seylers Z Physiol Chem 253: 1235–1245CrossRefGoogle Scholar
  54. 54.
    Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2: 125–140PubMedGoogle Scholar
  55. 55.
    Walsh PC, Hicks LL (1979) Characterisation and measurement of androgen receptors in human prostatic tissue. Prog Clin Biol Res 33: 51–63PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • G. Bartsch
  • P. J. Oefner
  • J. Eberle
    • 1
  1. 1.Universitätsklinik für UrologieInnsbruckAustria

Personalised recommendations